Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

123 ARTÍCULOS , VIENDO DEL 91 AL 105

Alzheimer’s disease, cerebrovascular disease, and the β-amyloid cascade

Honjo K, Black SE, Verhoeff NP.

Can J Neurol Sci. 2012 Nov;39(6):712-28. doi: 10.1017/s0317167100015547.

Alzheimer's dementia: a brief review

Bassil N, Mollaei C.

J Med Liban. 2012 Oct-Dec;60(4):192-9.

Alzheimer's disease: an update

Sharma J.

Nurs J India. 2012 Nov-Dec;103(6):245-8.

Alzheimer's disease and age-related macular degeneration have different genetic models for complement gene variation

Proitsi P, Lupton MK, Dudbridge F, Tsolaki M, Hamilton G, Daniilidou M, Pritchard M, Lord K, Martin BM, Johnson J, Craig D, Todd S, McGuinness B, Hollingworth P, Harold D, Kloszewska I, Soininen H, Mecocci P, Velas B, Gill M, Lawlor B, Rubinsztein DC, Brayne C, Passmore PA, Williams J, Lovestone S, Powell JF.

Neurobiol Aging. 2012 Aug;33(8):1843.e9-17. doi: 10.1016/j.neurobiolaging.2011.12.036. Epub 2012 Feb 1.

Variability in blood-based amyloid-beta assays: the need for consensus on pre-analytical processing

Watt AD, Perez KA, Rembach AR, Masters CL, Villemagne VL, Barnham KJ.

J Alzheimers Dis. 2012;30(2):323-36. doi: 10.3233/JAD-2012-120058.

Rapidly progressive Alzheimer's disease: a multicenter update

Schmidt C, Haïk S, Satoh K, Rábano A, Martinez-Martin P, Roeber S, Brandel JP, Calero-Lara M, de Pedro-Cuesta J, Laplanche JL, Hauw JJ, Kretzschmar H, Zerr I.

J Alzheimers Dis. 2012;30(4):751-6. doi: 10.3233/JAD-2012-120007.

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease

Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E; AAB-001 201/202 Investigators.

Arch Neurol. 2012 Aug;69(8):1002-10. doi: 10.1001/archneurol.2012.90.

Does Alzheimer's disease with early onset progress faster than with late onset? A case-control study of clinical progression and cerebrospinal fluid biomarkers

Grønning H, Rahmani A, Gyllenborg J, Dessau RB, Høgh P.

Dement Geriatr Cogn Disord. 2012;33(2-3):111-7. doi: 10.1159/000337386. Epub 2012 Apr 12.

Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play

Jack CR Jr.

Radiology. 2012 May;263(2):344-61. doi: 10.1148/radiol.12110433.

Cerebrospinal fluid biomarkers in Alzheimer's disease and geriatric depression: preliminary findings from Brazil

Reis T, Brandão CO, Freire Coutinho ES, Engelhardt E, Laks J.

CNS Neurosci Ther. 2012 Jul;18(7):524-9. doi: 10.1111/j.1755-5949.2012.00311.x. Epub 2012 Apr 25.

Comparison of imaging biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging

Whitwell JL, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Roberts RO, Boeve BF, Petersen RC, Jack CR Jr; Alzheimer Disease Neuroimaging Initiative.

Arch Neurol. 2012 May;69(5):614-22. doi: 10.1001/archneurol.2011.3029.

[Biological markers in the diagnosis of dementia and Alzheimer's disease]

Meiner Z, Rosenmann H.

Harefuah. 2012 May;151(5):289-93, 318.

The imbalance of vascular molecules in Alzheimer's disease

Bell RD.

J Alzheimers Dis. 2012;32(3):699-709. doi: 10.3233/JAD-2012-121060.

Diagnostic and economic evaluation of new biomarkers for Alzheimer's disease: the research protocol of a prospective cohort study

Handels RL, Aalten P, Wolfs CA, OldeRikkert M, Scheltens P, Visser PJ, Joore MA, Severens JL, Verhey FR.

BMC Neurol. 2012 Aug 10;12:72. doi: 10.1186/1471-2377-12-72.

Association of the CR1 polymorphism with late-onset Alzheimer's disease in Chinese Han populations: a meta-analysis

Jin C, Li W, Yuan J, Xu W, Cheng Z.

Neurosci Lett. 2012 Oct 3;527(1):46-9. doi: 10.1016/j.neulet.2012.08.032. Epub 2012 Aug 27.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias